Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

作者：Marc‐Oliver Grimm, Emilio Esteban, Philippe Barthélémy, Manuela Schmidinger, Jonas Busch, Begoña P. Valderrama, Natalie Charnley, Marc Schmitz, Ulrike Schumacher, Katharina Leucht, Susan Foller, Gustavo Baretton, Ignacio Durán, Guillermo de Velasco, Frank Priou, Pablo Maroto, Laurence Albigès, C. Barone, Daniel Castellano, Christine Chevreau, P. Gajate Borau, Srinavasan Gopalakrishnan, Enrique Grande, Abdel Hamid, Julia Heinzelbecker, Martin Janssen, Jindřich Kopecký, Eugen Kubala, Wolfgang Loidl, Anja Lorch, Bohuslav Melichar, Nuria Laínez Milagro, Günter Niegisch, Carsten‐Henning Ohlmann, Anne Sacré, Naveed Sarwar, Giovanni Schinzari, Dirk Schrijvers, Sophie Tartas, Manfred Wirth, Pascal Wolter, Milanda Zemanova · 发表于：The Lancet Oncology · 年份：2023 · DOI：10.1016/s1470-2045(23)00449-7 · 被引用次数：36 · 研究领域：Renal cell carcinoma treatment、Cancer Immunotherapy and Biomarkers、Ferroptosis and cancer prognosis